MSD Japan’s Sales Surge 7.5% in 2021, 1.5% Growth If Lagevrio Excluded: President

MSD Japan President Kyle Tattle MSD Japan saw its 2021 sales grow 7.5% over the prior year to 289 billion yen, driven by its COVID-19 pill Lagevrio (molnupiravir), but if this drug was excluded, the growth was “much more modest”...read more